Curated News
By: NewsRamp Editorial Staff
September 22, 2026
Tonix Expands TONMYA Medicare Coverage to 32M Lives, Sales Force to 150
TLDR
- Tonix expands TONMYA Medicare coverage to 32 million lives and field sales force to 150 representatives, strengthening its competitive position in fibromyalgia treatment.
- Tonix secures a second managed Medicare agreement for TONMYA, adding 21 million lives and raising total payer coverage to 166 million through commercial and government channels.
- Tonix's TONMYA, the first new fibromyalgia treatment in over 15 years, now reaches more patients through expanded Medicare and commercial insurance coverage.
- Tonix Pharmaceuticals' TONMYA sublingual tablets for fibromyalgia now cover 53 percent of U.S. lives, with 150 sales reps promoting the first new option in 15 years.
Impact - Why it Matters
This news matters because it significantly improves access to a novel treatment for fibromyalgia, a chronic pain condition affecting millions of Americans who have had few new options for over 15 years. With TONMYA now covered for 53% of the U.S. population, more patients can afford and receive this therapy, potentially transforming their quality of life. For investors, the expanded payer coverage and enlarged sales force signal strong commercial execution and a growing revenue trajectory for Tonix Pharmaceuticals. The agreement also highlights the company's ability to navigate the complex U.S. healthcare reimbursement landscape, which is critical for the success of any new drug. As Tonix continues to advance its pipeline in CNS and immunology, this milestone reinforces its position as a rising player in the biotech industry.
Summary
Tonix Pharmaceuticals (NASDAQ: TNXP) has announced a second major managed Medicare agreement for TONMYA(R) (cyclobenzaprine HCl sublingual tablets), its flagship treatment for fibromyalgia in adults, effective immediately. This new agreement adds approximately 21 million Medicare lives, bringing total Medicare coverage to roughly 32 million lives—about 58% of the approximately 55 million Medicare beneficiaries in the U.S. Combined with commercial and government payer coverage, TONMYA(R) now reaches approximately 166 million covered lives, representing 53% of the total U.S. population of about 314 million. This significant expansion underscores Tonix's growing commercial footprint in the fibromyalgia market.
In addition to the payer wins, Tonix has fully activated approximately 50 new sales representatives, bringing its total sales force to 150. The company had previously secured commercial payer agreements with two leading group purchasing organizations and one major managed Medicare agreement, while TONMYA(R) is also covered by Medicaid in nearly all states. These moves are part of Tonix's broader strategy to maximize patient access to the first new fibromyalgia treatment in more than 15 years. To view the full press release, visit https://ibn.fm/Q8TKY.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet need. Beyond TONMYA, its CNS portfolio includes acute migraine products Zembrace(R) SymTouch(R) and Tosymra(R), as well as TNX-2900 for Prader-Willi syndrome. The company is also advancing immunology programs such as TNX-4800 for Lyme disease prophylaxis and TNX-1500 for kidney transplant rejection. The latest news and updates relating to TNXP are available in the company’s newsroom at https://ibn.fm/TNXP.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Tonix Expands TONMYA Medicare Coverage to 32M Lives, Sales Force to 150
